Ipsen
13
43M
10
0.14
1
0.23
3
- Areas of investment
Summary
Ipsen is the famous Corporate Investor, which was founded in 1929. The main office of represented Corporate Investor is situated in the Boulogne-billancourt. The venture was found in Europe in France.
Speaking about the real fund results, this Corporate Investor is 9 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2017. The important activity for fund was in 2019. This Ipsen works on 4 percentage points more the average amount of lead investments comparing to the other organizations.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Ipsen, startups are often financed by New Enterprise Associates, MPM Capital, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Third Rock Ventures, New Enterprise Associates, MPM Capital. In the next rounds fund is usually obtained by Third Rock Ventures, SV Health Investors, Pfizer Venture Investments.
The current fund was established by Henri Beaufour.
Among the most popular fund investment industries, there are Biotechnology, Health Care. Among the various public portfolio startups of the fund, we may underline Thesan Pharmaceuticals, Pyxis Oncology, Pyxis Oncology For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 1
- Exits
- 3
- Rounds per year
- 0.14
- Follow on index
- 0.23
- Investments by industry
- Biotechnology (10)
- Health Care (10)
- Pharmaceutical (7)
- Therapeutics (7)
- Drug Discovery (1) Show 7 more
- Investments by region
-
- United States (11)
- United Kingdom (1)
- Italy (1)
- Peak activity year
- 2012
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 40M
- Group Appearance index
- 0.85
- Avg. company exit year
- 8
- Avg. multiplicator
- 2.43
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | 27 Nov 2012 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 33M | United States, Massachusetts, Boston |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.